GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Price-to-Funds-From-Operations

Orphazyme AS (CHIX:ORPHAC) Price-to-Funds-From-Operations : (As of Jun. 23, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


Orphazyme AS (CHIX:ORPHAC) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).